These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 39199640)

  • 1. Profiling the Cardiovascular Toxicities of CDK4/6 Inhibitors: A Real-World Pharmacovigilance Study.
    Kim JH
    Cancers (Basel); 2024 Aug; 16(16):. PubMed ID: 39199640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study.
    Lin W; Zeng Y; Weng L; Yang J; Zhuang W
    BMC Pharmacol Toxicol; 2024 Aug; 25(1):47. PubMed ID: 39123221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system.
    Shen J; Luo P; Xu J
    Ther Adv Drug Saf; 2024; 15():20420986241278498. PubMed ID: 39376495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system.
    Xiao Z; Cao J; Wu S; Zhou T; Li C; Duan J; Yang Z; Xu F
    CNS Neurosci Ther; 2024 Jul; 30(7):e14862. PubMed ID: 39009505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database.
    Chen J; Tang L; Song W; Sun C; Zhang W
    Front Pharmacol; 2024; 15():1371346. PubMed ID: 39011505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation.
    Hua M; Xiong F; Chong S; Zhang Z; Liu Q; Hou J; Zhang Z; Gu Z; Cui X; Cui Y; Xu L; Xiang Q
    Cancer Treat Rev; 2024 Nov; 130():102827. PubMed ID: 39278067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting system.
    Yan Y; Wu B; Wang L
    Expert Opin Drug Saf; 2024 Sep; 23(9):1191-1198. PubMed ID: 38482864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Fusaroli M; La Placa M; Ardizzoni A; Zamagni C; Poluzzi E; De Ponti F
    Am J Clin Dermatol; 2022 Mar; 23(2):247-255. PubMed ID: 34699032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.
    Raschi E; Fusaroli M; Ardizzoni A; Poluzzi E; De Ponti F
    Breast Cancer Res Treat; 2021 Feb; 186(1):219-227. PubMed ID: 33150548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological and Psychiatric Adverse Events Associated with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer Patients: Insights from a Pharmacovigilance Study via the FDA Adverse Event Reporting System.
    Yu Z; Guan M; Liao X
    Clin Drug Investig; 2024 Oct; 44(10):789-798. PubMed ID: 39392584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System.
    Martins V; Jesus M; Pereira L; Monteiro C; Duarte AP; Morgado M
    Pharmaceuticals (Basel); 2023 Sep; 16(10):. PubMed ID: 37895811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
    Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
    Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021.
    Wang Y; Cui C; Ren X; Dong X; Cui W
    Front Cardiovasc Med; 2022; 9():988013. PubMed ID: 36312283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDK4/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug-gene interaction network.
    She Y; Guo Z; Zhai Q; Liu J; Du Q; Zhang Z
    Front Pharmacol; 2024; 15():1378090. PubMed ID: 38633610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A disproportionality analysis of CDK4/6 inhibitors in the FDA Adverse Event Reporting System (FAERS).
    Peng Y; Zhou Y; Zhou X; Jia X; Zhong Y
    Expert Opin Drug Saf; 2024 Aug; ():1-9. PubMed ID: 39083396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Cardiovascular Events with Cyclin-Dependent Kinases 4 and 6 (CDK 4/6) Inhibitors among Patients with Advanced Breast Cancer: A Systematic Review and Network Meta-Analysis.
    Liu YS; Dong K; Park C
    Rev Cardiovasc Med; 2023 Nov; 24(11):309. PubMed ID: 39076428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database.
    Zhao H; Li JM; Li ZR; Zhang Q; Zhong MK; Yan MM; Qiu XY
    Front Pharmacol; 2023; 14():1182113. PubMed ID: 37502210
    [No Abstract]   [Full Text] [Related]  

  • 19. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
    Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapies for HR+/HER2-breast cancer: Systematic review and network meta-analysis.
    Tong F; Lu Y; Ma HF; Shen J
    Heliyon; 2024 Jun; 10(11):e31583. PubMed ID: 38832268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.